2025
Treatment of Melasma Using Low-Fluence QS Nd: YAG (1064 nm) Laser: A Blind, Randomized, Placebo-Controlled Trial.
Sadeghpour M, Laughter M, Rizzo S, Depina J, Petrell K, Arndt K, Dover J. Treatment of Melasma Using Low-Fluence QS Nd: YAG (1064 nm) Laser: A Blind, Randomized, Placebo-Controlled Trial. Dermatologic Surgery 2025 PMID: 40932145, DOI: 10.1097/dss.0000000000004846.Peer-Reviewed Original ResearchTreatment of melasmaHydroquinone 4%Patient-reported improvementQS-NdMelanin indexFitzpatrick skin types I-IVSkin types I-IVQS Nd:YAG laserPlacebo-controlled trialLaser treatment groupMelasma severity scoreSplit face trialStatistically significant differenceMMASI scoreTopical therapyPlacebo-ControlledTypes I-IVMonths treatmentFollow-upInadequately controlled studiesWeek 8Severity scoreTreatment protocolsMelasmaTreatment groups
2023
Extension Phase of a Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Wang J, Fabi S, Robinson D, Bajaj S, Geronemus R, Bell M, Robison T, Widgerow A. Extension Phase of a Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia. Journal Of Drugs In Dermatology 2023, 23: 1266-1270. PMID: 38206144, DOI: 10.36849/jdd.7622.Peer-Reviewed Original ResearchConceptsFacial dyschromiaMulti-center trialClinical studiesBlinded clinical studyTopical productsALS cohortExtension studyHydroquinone 4%Follow-up visitExtension phaseClearance of pigmentAssociated with increased productionMulti-centerDaily sunscreen useReduced clearanceCohortDyschromiaSunscreen useIn vitroWeeksTrialsLong-term basisSignificant reboundSkinEfficacyA Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Wang J, Fabi S, Robinson D, Bajaj S, Geronemus R, Bell M, Widgerow A. A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia. Journal Of Drugs In Dermatology 2023, 22: 333-338. PMID: 37026875, DOI: 10.36849/jdd.7340.Peer-Reviewed Original ResearchConceptsModified Melasma Area Severity IndexHydroquinone 4%Post-inflammatory hyperpigmentationFacial dyschromiaBlinded clinical studyFollow-upClinical studiesTopical productsAdverse eventsModified melasma area severity index scoreMulti-centerMelasma Area Severity IndexArea Severity IndexNo adverse eventsClearance of pigmentIn vitro studiesExcessive sun exposureBlinded investigatorRight cheekWeek 4Griffiths ScalesReduced clearanceSun exposureMedical disordersTolerability assessments
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply